Sophia’s DDM has analysed the genomic profiles of more than two million patients since its launch in 2015. Image credit: T. Schneider via Shutterstock.com.

Sophia Genetics and Element Biosciences have teamed up to advance genomic sequencing and workflows for precision medicine.

Announced during the Association for Molecular Pathology (AMP) meeting, taking place on11-15 November in Boston, the collaboration will integrate Sophia Genetics’ AI-powered analytics platform, SOPHiA DDM, with Element’s AVITI24 5D multiomic and AVITI sequencing systems.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

According to the companies, integrating their respective technologies will advance genomic research workflows to support labs’ development of precision medicines.

Element’s AVITI24: 5D Multiomic Platform is designed for single-cell, spatial multiomics, capturing dynamic response, morphology, protein, RNA, and spatial context within a single assay.

The platform is complemented by AVITI next-generation sequencing (NGS) platform. NGS is a method for sequencing DNA or RNA that is capable of analysing millions of genetic fragments simultaneously.

Sophia’s DDM is a cloud-based platform that interprets genomic and multimodal data using AI and machine learning (ML). Through contributions from 800 healthcare institutions across 72 countries, DDM will be able to regularly refine its AI capabilities. In March 2025, Sophia’s DDM had analysed the genomic profiles of more than two million patients since its 2015 launch.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Sophia Genetics’ CEO and co-founder Jurgi Camblong commented: “This partnership aligns with our shared goals of democratising access to research that supports precision medicine globally, bringing data-driven decisions closer to home, and extending the reach of our respective technologies.”

According to GlobalData analysis, the overall application of AI across healthcare will reach a valuation of $19bn by 2027.

In a testimonial for the companies, Professor Hagay Sobol, head of the Molecular Oncogenetics Laboratory at France’s Institut Paoli-Calmettes, said: “We expect this collaboration that pairs Sophia Genetics’ powerful analytics with Element’s sequencing performance will be able to deliver the consistency and scalability needed for research that helps bring precision medicine to more patients, faster.”

The next-generation sequencer market is growing at a compound annual growth rate (CAGR) of 11.2% and is forecast to reach a valuation of $18.5m by 2034, up from $6.4m in 2024, according to GlobalData.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact